Clonal B-cell Lymphocytosis Exhibiting Immunophenotypic Features Consistent with a Marginal-zone Origin: is This a Distinct Entity?
Overview
Authors
Affiliations
The biological and clinical significance of a clonal B-cell lymphocytosis with an immunophenotype consistent with marginal-zone origin (CBL-MZ) is poorly understood. We retrospectively evaluated 102 such cases with no clinical evidence to suggest a concurrent MZ lymphoma. Immunophenotyping revealed a clonal B-cell population with Matutes score ≤2 in all cases; 19/102 were weakly CD5 positive and all 35 cases tested expressed CD49d. Bone marrow biopsy exhibited mostly mixed patterns of small B-lymphocytic infiltration. A total of 48/66 (72.7%) cases had an abnormal karyotype. Immunogenetics revealed overusage of the IGHV4-34 gene and somatic hypermutation in 71/79 (89.8%) IGHV-IGHD-IGHJ gene rearrangements. With a median follow-up of 5 years, 85 cases remain stable (group A), whereas 17 cases (group B) progressed, of whom 15 developed splenomegaly. The clonal B-cell count, degree of marrow infiltration, immunophenotypic, or immunogenetic findings at diagnosis did not distinguish between the 2 groups. However, deletions of chromosome 7q were confined to group A and complex karyotypes were more frequent in group B. Although CBL-MZ may antedate SMZL/SLLU, most cases remain stable over time. These cases, not readily classifiable within the World Heath Organization classification, raise the possibility that CBL-MZ should be considered as a new provisional entity within the spectrum of clonal MZ disorders.
Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma.
Zhang Q, Yan W, Li H, Peng H Curr Treat Options Oncol. 2025; 26(2):142-155.
PMID: 39891871 DOI: 10.1007/s11864-025-01293-w.
Hoe R, Xu Z, Singh R Case Rep Neurol Med. 2024; 2024:6620797.
PMID: 39624067 PMC: 11611394. DOI: 10.1155/crnm/6620797.
Cox M, Esposito F, Postorino M, Venditti A, Di Napoli A Cancers (Basel). 2023; 15(18).
PMID: 37760410 PMC: 10527377. DOI: 10.3390/cancers15184440.
Management of marginal zone lymphomas.
Merli M, Arcaini L Hematology Am Soc Hematol Educ Program. 2022; 2022(1):676-687.
PMID: 36485086 PMC: 9901419. DOI: 10.1182/hematology.2022000362.
CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen.
Schmieg J, Muir J, Aguilera N, Auerbach A Curr Oncol. 2021; 28(6):5124-5147.
PMID: 34940069 PMC: 8700451. DOI: 10.3390/curroncol28060430.